Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.

Prostate Cancer Clinical Trial

— RCT-EPAII-BCR  

Official title:

Étude Pilote randomisée de Phase IIB, contrôlée Par placébo, évaluant l'Effet thérapeutique d'Une supplémentation en Omega-3 (Principalement EPA) Chez Des Patients en récidive Biochimique ou en Progression du Cancer de la Prostate.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03753334
• Other study ID #: 2017-3407
• Status: Recruiting
• Phase: Phase 2
• Start date: July 10, 2017
• Est. completion date: December 2025

Study information

• Verified date: September 2023
• Source: CHU de Quebec-Universite Laval
• Contact: Vincent Fradet, MD, PhD
• Phone: 418-525-4444
• Email: vincent.fradet[@]fmed.ulaval.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prostate cancer biochemical recurrence (BCR) occurs in 20-50% of patients following radical prostatectomy or radiotherapy. Due to significant risk of side effects and uncertainty about the benefits, physicians and patients are seeking alternatives to delay androgen deprivation therapy (ADT) for non-metastatic BCR. Long-chain omega-3 fatty acids (LCn3), mainly found in seafood and fatty fish, have beneficial effects against prostate cancer in pre-clinical experimental studies and randomized clinical trials of intermediate prostate cancer outcomes. The current observational evidence also supports testing LCn3 in prostate cancer patients. LCn3 have beneficial effects on inflammation, cardiovascular, psychological, and other outcomes, contrasting sharply with ADT-associated side effects.

Investigators propose to conduct a pilot randomized placebo-controlled trial to determine the effects over one year of an innovative LCn3 supplement (5g of omega-3-rich fish oil daily, including 4g of monoglycerides eicosapentaenoic acid (MAG-EPA)) in 40 men experiencing BCR or prostate cancer progression after a curative treatment.

This project proposes a simple intervention by dietary supplementation that could eventually help to prevent or delay ADT-related side effects and thus could contribute to diminish the heavy individual and societal burden of prostate cancer. The clinical data generated by this pilot trial will serve as basis for a larger-scale phase II clinical trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Patients must have a histologically or cytologically confirmed history of adenocarcinoma of the prostate.

• Patients must have a PSA failure defined as PSA of >= 0.5 ng/ml that has increased above nadir following radical prostatectomy (RP); or a PSA increase of 2.0 above post-therapy nadir after radiotherapy (RT); or a PSA increase between 0.05-0.49 ng/ml that has increased above nadir following RP. The maximal PSA value at enrolment must be <5.0 ng/mL after RP and <6 ng/mL after RT.

• PSA value must be increasing based on three consecutive measurements each separated by at least 4 weeks prior to enrolment to this study.

• Patients may have received any number of local therapies (RP, external beam RT or brachytherapy).

• Provide written informed consent.

Exclusion Criteria:

• Patients with evidence of metastatic disease.

• Patients who have received prior cytotoxic chemotherapy for recurrent disease.

• Patients currently receiving biological response modifiers, or corticosteroids.

• Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situations that would limit compliance with study requirements.

• Use of omega-3 or any other dietary supplements for the previous 3 months and during study is not allowed.

• Known allergy to fish or shellfish or sunflower.

Related Conditions & MeSH terms

• Disease Progression
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Combination Product:
• MAG-EPA
5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months

Dietary Supplement:
• Placebo group
5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months

Locations

Country	Name	City	State
Canada	Centre de Recherche Clinique et Évaluative en Oncologie - Hôtel-Dieu de Québec	Québec	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Quebec-Universite Laval

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prostate-specific antigen (PSA) doubling time from baseline to 12 months.	Efficacy of a one-year MAG-EPA supplementation versus placebo on PSA kinetics will be evaluated based on the comparison of PSA doubling time from baseline to 12 months. The investigators will measure PSA level every three months and calculate PSA doubling time at 12 months (using a linear regression approach) after randomisation using the randomisation PSA value as the starting point. PSA slope will be defined as the linear regression line of the natural log of PSA (in ng/mL) against time (in months). PSA doubling time will be defined as the natural log of 2 divided by the PSA slope.	12 months
Secondary	Fatty acid profiles in red blood cells, changes relative to baseline (time 0).	The changes of fatty acid levels in red blood cell membranes, relative to their baseline levels, will be measured every three months. The profile of fatty acids will be quantified using gas chromatography coupled with mass spectrometry and expressed as relative percentages of total fatty acids.	3, 6, 9,12 months